Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334413 | PMC |
| http://dx.doi.org/10.1007/s00277-017-2938-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
Leukemia
December 2024
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
CRLF2 rearrangements occur in >50% of Ph-like and Down syndrome (DS)-associated B-acute lymphoblastic leukemia (ALL) and induce constitutive kinase signaling targetable by the JAK1/2 inhibitor ruxolitinib under current clinical investigation. While chimeric antigen receptor T cell (CART) immunotherapies have achieved remarkable remission rates in children with relapsed/refractory B-ALL, ~50% of CD19CART-treated patients relapse again, many with CD19 antigen loss. We previously reported preclinical activity of thymic stromal lymphopoietin receptor-targeted cellular immunotherapy (TSLPRCART) against CRLF2-overexpressing ALL as an alternative approach.
View Article and Find Full Text PDFSuccessful ruxolitinib rechallenge after fedratinib failure in a patient with overt myelofibrosis.
Ann Hematol
November 2024
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Hematology
December 2022
Department of Hemato-Oncology, Erasme Hospital, Brussels, Belgium.
Objectives: Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the only approved and reimbursed pharmacotherapy for non-HSCT candidates in Belgium is ruxolitinib.
Methods: These updated recommendations are based on a consensus reached during two meetings and provide guidance for ruxolitinib administration in myelofibrosis patients considering the particularities of Belgian reimbursement criteria.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
August 2021
Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G. F. Ingrassia, " University of Catania, Italy.
Background: After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor with scarce therapeutic possibilities.
Methods: The authors performed a subanalysis of an observational, retrospective study (RUX-MF) that included 703 MF patients treated with ruxolitinib to investigate 1) the frequency and reasons for ruxolitinib rechallenge, 2) its therapeutic effects, and 3) its impact on overall survival.
Results: A total of 219 patients (31.
Management of myelofibrosis after ruxolitinib failure.
Ann Hematol
June 2020
University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Article Synopsis
- Myelofibrosis is a serious blood disorder characterized by symptoms like anemia, enlarged spleen, and bone marrow issues, with current treatments mainly focused on JAK inhibitors, particularly ruxolitinib.
- Ruxolitinib is effective for many patients but often leads to side effects and resistance over time, making ongoing treatment challenging.
- Newer JAK inhibitors like fedratinib, pacritinib, and momelotinib show promise for patients who do not respond well to ruxolitinib, with some improving symptoms and spleen size significantly.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!